CTOs on the Move


 
Genexa is the world`s first and only clean medicine company and was recognized in 2022 by Fast Company as the no. 1 Most Innovative Company in Wellness. We were founded in 2016 by two dads who believed medicine should only have the active ingredients you need, and not the artificial fillers you don`t. It`s medicine made clean, because that`s what people deserve. Our headquarters is located in Atlanta, where we strive to put people over everything
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.genexa.com
  • 1510 Ellsworth Industrial Boulevard NW Building Two, Suite 10
    Atlanta, GA USA 30318
  • Phone: 855.436.3921

Executives

Name Title Contact Details

Similar Companies

Top RX

If you think all generic pharmaceutical distributors are alike, it’s time to think again. We’re TOP RX, a leading national generic distributor that helps more than 5,000 pharmacies keep prices low on more than 2,800 generic pharmaceuticals. We call our company “TOP” for several reasons. We bring value to your business in many ways including our technological solutions, guaranteed product credibility and competitive pricing.

GeNOsys

GeNOsys (generated nitric oxide systems) Inc. is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas

Afexa Life Sciences

Afexa Life Sciences Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.

Galera Therapeutics

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.